NAPMS
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Natalizumab
Integrin alpha-4/beta-1 inhibitor|Integrin alpha-4/beta-7 inhibitor
What it measured
Main measures
The primary endpoint is change in CSF osteopontin from baseline (week 0) to week 60. CSF osteopontin will be meassured by the ELISA technique.
Blood or spinal fluid markers
Who could take part
Progressive MS
Inclusion: Age between 19 and 55 years Exclusion: Pregnancy, breast-feeding or lack of anti.conception for fertile women.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To study safety and efficacy of natalizumab treatment of primary and secondary progressive multiple sclerosis. This will be done by measuring the effect of treatment on inflammation in the CNS by means of osteopontin levels in the cerebrospinal fluid (CSF). Safety measures further includes physical and neurological exmination, blood samples and MRI measures of disease activity.
Loading reviews and guidelines…
Related trials
- NAPMS
Phase 2 · Completed
Result in a paper, not read yet
History
Started
Nov 2009
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error